DNB Respiratory Medicine previous-year questions (2020–2025)

“The bronchial circulation.”

“Blood supply of lung.”

“Bronchopulmonary segments of human lung.”

“Collateral ventilation.”

“Congenital agenesis of lung.”

“Congenital diaphragmatic hernia.”

“Stages of lung development.”

“Post natal lung development.”

“Development of the airways and blood vessels.”

“Stages of lung development.”

“Stockers classification of Congenital Pulmonary Airway Malformation (CPAM).”

“Aging lung.”

“Aging lung.”

“Type 2 alveolar epithelial cell structure and functions.”

“Alveolar Epithelium.”

“Pneumocytes.”

“Define non-responding pneumonia and enumerate the causes.”

“Approach to a case with non-resolving pneumonia.”

“Enumerate Old and Re-purposed Drugs used or under evaluation for the treatment of COVID-19.”

“Casirivimab-Indevimab.”

“Baricitinib.”

“IL-6 inhibition in COVID-19.”

“Remdesivir.”

“Role of Monoclonal antibody treatment for COVID-19.”

“Convalescent plasma in the management of COVID-19.”

“Vaccine in Covid-19.”

“Vaccination against COVID-19: types of vaccines and side effects.”

“Vaccine hesitancy.”

“Enumerate different strategies available for prevention against Corona virus.”

“Precautionary dose of Covid-19 vaccine.”

“Evaluation and management of COVID-19 case in adults.”

“Home and hospital management of COVID-19 disease.”

“Caring for the critically ill patient with COVID-19.”

“Aetiology and severity assessment of community acquired pneumonia.”

“Assessment of severity of community acquired pneumonia.”

“Management of CAP in out-patient setting.”

“Causative organisms, diagnostic work-up and principles of treatment of community acquired pneumonia.”

“Empiric antibiotic selection in adults outpatient of community-acquired pneumonia.”

“Corticosteroids in COVID-19.”

“Glucocorticoids in the management of COVID-19.”

“Mutations in lung cancer.”

“Briefly describe the various driver mutations for lung cancer.”

“ROS1 translocations in non small cell lung carcinoma and implications.”

“Briefly describes the mutations of clinical interest for non-small cell lung cancer.”

“Enlist the driver mutations responsible for tumour progression in non-small cell lung cancer. Mention limitation and toxicity of tyrosine kinase inhibitors in the management of non-small cell lung cancer.”

“Liquid biopsies tests for lung cancer patients.”

“Liquid biopsy for lung cancer.”

“Liquid biopsy tests for lung cancer patients.”

“Genetic susceptibility to lung cancer.”

“What are the various mechanisms for genetic mutations of lung cancer.”

“Screening for lung cancer.”

“Patient selection and implementation in lung cancer screening.”

“Leveraging lung cancer imaging for COPD screening.”

“Electrolyte imbalance in small cell lung carcinoma.”

“Factors affecting prognosis of non-small cell lung carcinoma (NSCLC).”

“Approach to moderate pleural effusion.”

“Enumerate various causes of recurrent non-malignant pleural effusion.”

“Biochemical tests for diagnostic evaluation of pleural effusion.”

“Transudative pleural effusion.”

“Indications and complications of ICD insertion in pleural effusion.”

“Relative contraindications and complications of pleural aspiration.”

“Indications of intercostal drain insertion and drain size.”

“Management of surgical (subcutaneous) emphysema following chest drain insertion.”

“Assessment of a non-functioning chest drain.”

“Pleural biopsy.”

“Complications of pleural biopsy.”

“Abraham and Cope's pleural biopsy needles.”

“Pleural effusions in the critically ill and “At-Bleeding-Risk” population.”

“Pleural ultrasonography.”

“Ultrasonography in pleural effusion.”

“Bacterial empyema.”